Mdivi-1 and the SP1–ADAM10–DRP1 Axis in HPH
2026-10-12
Mdivi-1 is used in a 2025 study as a pharmacological perturbation of DRP1-linked signaling in hypoxia pulmonary hypertension. The findings connect endothelial ADAM10 with smooth-muscle-cell behavior through DRP1 and PI3K/AKT/mTOR-associated pathways, but they do not establish that Mdivi-1 effects are uniquely attributable to DRP1 or that the compound is a treatment for pulmonary hypertension.
A Reporter-Based Strategy for Rabbit Pharming
2026-10-12
Song et al. investigated whether directing transgene expression through the native rabbit β-casein promoter could improve recombinant-protein production in milk. Their reporter-based knock-in line showed substantially higher reported milk concentrations in homozygous animals than many historical examples, but the evidence remains an early proof of concept rather than validation of a broadly transferable manufacturing platform.
Entinostat (MS-275): Evidence and Research Context
2026-10-10
Entinostat, also called MS-275 or SNDX-275, is a class I histone deacetylase inhibitor studied in cancer biology. This overview compares biochemical, cellular, preclinical and early clinical evidence, explains how to interpret cancer cell proliferation inhibition and apoptosis-related findings, and outlines limitations affecting retinoblastoma treatment research and solid tumor clinical trials.
ALDOB K87 Lactylation in Pulmonary Hypertension
2026-10-10
Yi et al. identify ALDOB K87 lactylation as a metabolic–mitochondrial link in pulmonary hypertension, connecting lactate accumulation with DRP1-dependent mitochondrial fission and pathological pulmonary artery smooth muscle cell behavior. The study provides mechanistic evidence across cell and rodent models while leaving important questions about patient heterogeneity, clinical relevance, and therapeutic translation.
Beyond Viability: Better In Vitro Drug Response Metrics
2026-10-09
Hannah Schwartz’s 2022 dissertation examines why relative viability and fractional viability should not be treated as interchangeable measures of anticancer drug response. Its central contribution is a framework for separating growth inhibition from cell killing, improving interpretation of timing, response magnitude, and translational relevance in cancer research.
GLP-1 Receptor Crosstalk in FRET cAMP Assays
2026-10-09
Chepurny and colleagues used high-throughput FRET-based cAMP measurements and molecular modeling to show that glucagon can activate the GLP-1 receptor under some assay conditions, challenging strict assumptions about receptor selectivity. The study also clarifies how orthosteric and allosteric ligands can reveal overlapping pharmacology, with implications for GLP-1 receptor signaling research and the interpretation of multi-receptor metabolic drugs.
SIRT1, Bone Aging, and Vascular–Osteogenic Repair
2026-10-08
Liu et al. show that reduced SIRT1 activity is associated with impaired endothelial and osteogenic function in aging-related bone defects, while pharmacological SIRT1 activation improves both processes in vitro and bone regeneration in vivo. The study links these effects to β-catenin deacetylation and nuclear signaling, offering a mechanistic framework for studying vascular–osteogenic coupling rather than evidence of clinical efficacy.
Carvacrol, TRPA1 and Redox Channel Signaling
2026-10-08
Carvacrol, also known as 5-isopropyl-2-methylphenol, appears in a 2026 study as a non-electrophilic TRPA1 agonist used to distinguish ligand-selective effects after singlet-oxygen exposure. This overview separates those findings from broader supplier claims about cell-cycle regulation, apoptosis, antibacterial activity and antioxidant properties, while outlining the study’s evidence strength, research relevance and applicability limits.
From Tau Ser356 to Translational Strategy
2026-10-07
Taylor et al. connect tau phosphorylation at Ser356 with Alzheimer’s disease pathology and report distinct responses to NUAK inhibition in mouse and human brain slice models. This thought-leadership analysis examines what those findings mean for mechanism-led research, where Linagliptin (BI-1356) may fit as a clearly identified comparator compound, and why tissue context, biomarker specificity, and evidence boundaries should shape translational decisions.
Gamithromycin (ML-1709460): Evidence Overview
2026-10-07
Gamithromycin, also known as ML-1709460, is a 15-membered semi-synthetic macrolide antibiotic investigated mainly in veterinary respiratory disease. This overview examines its ribosomal mechanism, pharmacokinetic and pharmacodynamic evidence, findings from a murine Pasteurella multocida lung-infection model, translational applications, and the limits of extending those results to cattle, pigs, other pathogens, or clinical treatment decisions.
Quizartinib (AC220): FLT3 Research Context
2026-10-06
A source-grounded overview of Quizartinib (AC220), FLT3 biology, AML research relevance, evidence from BP-CML studies, and key translational limitations.
Dexamethasone in Inflammation Research
2026-10-05
Dexamethasone is a widely studied glucocorticoid anti-inflammatory compound with reported applications spanning immune-cell maturation, mesenchymal stem cell differentiation, cancer-cell biology and neuroinflammation. This overview separates supplier-reported findings from independently established evidence, compares model systems and explains why the available product information cannot substitute for peer-reviewed primary studies.
Intravesical p21 mRNA-LNP Therapy for Bladder Cancer
2026-10-05
A 2026 FASEB Journal study evaluated lipid nanoparticles carrying chemically modified p21 mRNA for localized treatment of bladder cancer. The preclinical results support intravesical tumor-suppressor replacement as a promising delivery concept, while leaving important questions about clinical translation, formulation-specific behavior, durability, and patient heterogeneity.
Temafloxacin PK: Findings and Veterinary Relevance
2026-10-04
Dudley’s 1991 review synthesizes human pharmacokinetic evidence for temafloxacin, emphasizing high oral bioavailability, an approximately eight-hour terminal half-life, substantial urinary recovery, and renal-function-dependent interval adjustment. Its main contribution is the integration of disposition data with pharmacodynamic reasoning, while its applicability to veterinary macrolides such as Gamithromycin remains indirect and must not be treated as comparative efficacy evidence.
DAMGO and the Hidden Circuitry of Opioid Pain
2026-10-03
A translational perspective on DAMGO, µ-opioid receptor signaling, and the brain-to-spinal circuitry that may shape opioid-induced mechanical hypersensitivity and tolerance.